TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07365241: A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Sponsor: AbbVie · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 531 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$20,862,072

Rescue Site Savings

+$13,776,840

Unlock Full NCT07365241 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07365241 Rescue Dossier →